首页> 外文期刊>Journal of Breast Cancer >Clinical review of bilateral breast cancer
【24h】

Clinical review of bilateral breast cancer

机译:双侧乳腺癌的临床回顾

获取原文
           

摘要

Purpose Bilateral breast cancer is categorized as synchronous or metachronous. The aim of this study was to evaluate the characteristics of synchronous and metachronous breast cancers. Methods Between 1989 and 2003, 1111 patients were treated for breast cancer at Yeung-Nam University Hospital. We retrospectively analyzed 27 women with bilateral breast cancer. Results Among the 27 cases (2.4% of the patients) of bilateral cancers, 7(0.6%) were synchronous and 20(1.8%) were metachronous. The mean age of the patient with synchronous and metachronous cancer was 46.9 and 41.1 years, respectively. Eighty percent (16/20) of the metachronous cases were under the age of 50. For the metachronous cancers, 65% of the cases (13/20) were down-staged and at same stage, respectively, compared to the primary cancer. The ER, PR, C-erbB2 and p53 positivity was 20% (4/20), 15% 21.1% and 52.9% in metachronous cancers, respectively, compared to 65%, 60%, 31.6% and 41.2% in the primary cancers, respectively. During the mean follow up of 74.3 months, the recurrence rate and mortality rate was 42.9% and 28.6%, respectively, for the synchronous cancers, and 5% and 5%, respectively, for the metachronous cancers. Conclusion The stage of the metachronous cancer was lower than that of the primary cancer, and this was probably due to careful follow-up. The lower proportion of ER and/or PR positive tumor in metachronous cancer might be associated with the effect of tamoxifen treatment. The prognosis was less favorable for the synchronous cases than for the metachronous second breast cancers in this study.
机译:目的双边乳腺癌分为同步性或异时性。这项研究的目的是评估同步和异时乳腺癌的特征。方法1989年至2003年,在杨南大学医院对1111例乳腺癌进行了治疗。我们回顾性分析了27例双侧乳腺癌女性。结果在27例(占患者的2.4%)双侧癌中,有7例(0.6%)是同步的,有20例(1.8%)是异时的。同期和同期癌症患者的平均年龄分别为46.9岁和41.1岁。 80%(16/20)的同期病例年龄在50岁以下。与原发癌相比,对于同期癌症,分别有65%(13/20)病例处于下调阶段和处于同一阶段。异时性癌症的ER,PR,C-erbB2和p53阳性率分别为20%(4/20),15%21.1%和52.9%,而原发性癌症分别为65%,60%,31.6%和41.2% , 分别。在平均随访74.3个月期间,同期癌症的复发率和死亡率分别为42.9%和28.6%,而同期癌症的复发率和死亡率分别为5%和5%。结论异时性癌症的分期低于原发性癌症,这可能是由于认真的随访所致。异时癌中ER和/或PR阳性肿瘤的比例较低可能与他莫昔芬治疗的效果有关。在本研究中,同步病例的预后较异时性第二乳腺癌的预后差。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号